Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Dompe' Farmaceutici S.p.A.
Sponsor

Dompe' Farmaceutici S.p.A.

Italy Via Santa Lucia 6, 20122 Milan, Italy

About the sponsor

Research activity is concentrated in dry eye disease, atopic keratoconjunctivitis, ocular inflammatory conditions, and persistent corneal epithelial defect, with additional work in dry eye symptom control and ocular itching.

  • Recombinant human nerve growth factor ophthalmic treatment
  • Isocyclosporin A eye drop therapy
  • Cenegermin for corneal healing
  • Vehicle-controlled ocular symptom studies

The portfolio also includes investigations in corneal epithelial repair and inflammatory eye disease, reflecting a strong focus on surface ocular disorders.

About Specializations

Dompe' Farmaceutici S.p.A. runs clinical trials in conditions such as Atopic keratoconjunctivitis, Craniocerebral injury, Persistent corneal epithelial defect, Cerebral palsy, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

10 clinical trials

Craniocerebral injury

Recruiting

Phase 2a Study of Safety, Tolerability and Efficacy of Intranasal Cenegermin in Adults with Moderate to Severe Subacute Traumatic Brain Injury

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Persistent corneal epithelial defect

Recruiting

Cenegermin Eye Drops for Persistent Corneal Epithelial Defect in Patients with Persistent Corneal Epithelial Defect

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Cerebral palsy

Recruiting

Study of Cenegermin Nasal Spray for Safety and Tolerability in Children with Spastic Cerebral Palsy

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Atopic keratoconjunctivitis

Recruiting

A study testing DFL24498 eye drop solution to improve eye itching in adults with atopic keratoconjunctivitis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S,34R)-30-Ethyl-34-[(E,2R)-Hex-4-En-2-Yl]-4,7,10,12,15,19,25,28-Octamethyl-33-(Methylamino)-6,9,18,24-Tetrakis(2-Methylpropyl)-3,21-Di(Propan-2-Yl)-1-Oxa-4,7,10,13,16,19,22,25,28,31-Decazacyclotetratriacontane-2,5,8,11,14,17,20,23,26,29,32-Undecone Hydrochloride
  • Sponsor:Dompe' Farmaceutici S.p.A.

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Acute respiratory distress syndrome

Not recruiting

Study on the Effectiveness and Safety of Reparixin for Adults with Acute Respiratory Distress Syndrome

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Reparixin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Type 1 diabetes mellitus

Not recruiting

Study on the Effects and Safety of Ladarixin for Adults and Adolescents with Recent Onset Type 1 Diabetes

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Ladarixin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Study on the Effectiveness and Safety of DFL24412 and Ketoprofen Lysine in Patients with Chronic Low Back Pain

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gabapentin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Atopic keratoconjunctivitis

Not recruiting

Study on the Safety and Effectiveness of Isocyclosporin A Eye Drops for Adults with Atopic Keratoconjunctivitis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fluorescein Sodium
  • Sponsor:Dompe' Farmaceutici S.p.A.

Dry eye

Not recruiting

Study on the Safety and Effectiveness of Cenegermin Eye Drops for Patients with Dry Eye Disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Chloride
  • Sponsor:Dompe' Farmaceutici S.p.A.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.